ArsenalBio

ArsenalBio cut 99 jobs across teams and locations as it narrowed its research around in-vivo CAR-T programs.

The biotechnology company retained a smaller core team to advance the new strategy. The reduction removes a majority of ArsenalBio's workforce while shifting the company away from its previous cell-therapy development model.